Evidence map›Paper›PMID 35626162›Full record

ArticleCancers2022

COVID-19 Vaccination in Patients with Cancer.

Hitomi Suzuki, Tomohiro Akiyama, Nobuko Ueda, Satoko Matsumura, Miki Mori, Masatoshi Namiki, Norikazu Yamada, Chika Tsutsumi, Satoshi Tozaki, Hisayuki Iwamoto and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 3 countries.

Hitomi SuzukiDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.ORCID 0000-0002-3643-9862
Tomohiro AkiyamaAdvanced Research Laboratories, Tokyo City University, Tokyo 158-0082, Japan.ORCID 0000-0002-6720-8995
Nobuko UedaPeer Ring Association, Yokohama 224-0001, Japan.ORCID 0000-0002-0223-4949
Satoko MatsumuraPeer Ring Association, Yokohama 224-0001, Japan.
Miki MoriDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Masatoshi NamikiDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Norikazu YamadaDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Chika TsutsumiDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Satoshi TozakiDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Hisayuki IwamotoDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Shun ToriiDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Yuichiro OkuboDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Kiyosuke IshiguroDepartment of Breast and Endocrinology Surgery, Ichinomiya Nishi Hospital, Ichinomiya 494-0001, Japan.
Nishijin Hospital · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with cancer are concerned about the effects of the COVID-19 vaccination. We conducted an online survey on the COVID-19 vaccination status and side effects among patients with cancer in Japan between 8 and 14 August 2021. We included 1182 female patients with cancer aged 20-70 years and registered on an online patient website. Of the patients, 944 had breast cancer, 216 had gynecological cancer, 798 were undergoing drug/radiation therapy, and 370 were in follow-up. At the time of the survey, 885 patients had already received at least one dose. Of these, 580 had also received their second dose. The incidence rate of side effects was equivalent to previous reports. In patients with breast cancer, problems such as the onset or worsening of lymphedema or axillary lymphadenopathy metastasis requiring differential diagnosis were encountered following vaccination. A total of 768 patients were concerned about the vaccine at some point, and 726 consulted with their attending physicians about the timing or side effects of the vaccination. Of the 110 patients undergoing chemotherapy or radiation therapy, 75 adjusted the timing of the vaccination based on their therapy. The cross-analysis revealed that 81% of those who consulted their physician had received at least one dose of the COVID-19 vaccination compared with 65% of those who had not consulted their physician. Consulting with a physician about the COVID-19 vaccination was found to alleviate the concerns of patients with cancer and encourage them to get vaccinated.

Indexed as

cancerCOVID-19doctor–patient communicationonline questionnairevaccine

Identifiers

PMID35626162
PMCPMC9139318
OpenAlexW4281397184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.